UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
| | |
| | |
Date of Report (Date of Earliest Event Reported): | | March 3, 2016 |
________________________
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
________________________
|
| | | |
Delaware | 001-32335 | | 88-0488686 |
(State or other jurisdiction of incorporation) | (Commission File Number) | | (IRS Employer Identification No.) |
|
| |
11388 Sorrento Valley Road, San Diego, California | 92121 |
(Address of principal executive offices) | (Zip Code) |
|
| | |
Registrant’s telephone number, including area code: | | (858) 794-8889 |
Not Applicable
(Former name or former address, if changed since last report)
_________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) On March 3, 2016, James M. Daly was elected to the Board of Directors Halozyme Therapeutics, Inc. (the “Company”). Mr. Daly was elected to the class of directors with terms ending in 2018 and will stand for election to the Board by the Company’s stockholders at the Company’s 2018 annual meeting of stockholders. Mr. Daly will serve on the Board of Directors’ Nominating and Corporate Governance Committee. Mr. Daly will receive compensation for his services (currently consisting of cash retainers for Board and committee service and restricted stock awards) under our director compensation program applicable to all non-employee directors. The components of the non-employee director compensation program were described in our proxy statement for the 2015 Annual Meeting of Stockholders held on May 6, 2015.
There are no arrangements or understandings pursuant to which Mr. Daly was elected as a director and there are no related person transactions between the Company and Mr. Daly.
On March 7, 2016, the Company issued a press release announcing the election of Mr. Daly to the Company’s Board of Directors. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
|
| |
Exhibit No. | Description |
| |
99.1 | Press release dated March 7, 2016 |
| |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | | | |
| | | | |
| | HALOZYME THERAPEUTICS, INC. |
| | | | |
March 7, 2016 | | By: | | /s/ Harry J. Leonhardt |
| | Name: | | Harry J. Leonhardt, Esq.
|
| | Title: | | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary |
Exhibit Index
|
| | |
| | |
Exhibit No. | | Description |
| | |
99.1 | | Press release dated March 7, 2016 |
Exhibit 99.1
Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
HALOZYME APPOINTS JIM DALY TO BOARD OF DIRECTORS
SAN DIEGO - March 7, 2016 - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of Jim Daly to its board of directors. Mr. Daly is a biopharmaceutical executive with 30 years of experience leading U.S. and global businesses.
“We are very pleased to have Jim join our board,” said Dr. Helen Torley, president and chief executive officer. “With extensive experience in launching and building major brands, particularly in oncology, he will serve as a valuable resource to our directors and executive leadership team as we move toward the potential commercialization of our investigational drug PEGPH20.”
Mr. Daly previously served as executive vice president and chief commercial officer at Incyte Corporation from 2012 to 2015. Prior to Incyte, Daly was senior vice president of North America Commercial Operations, Global Marketing and Commercial Development for Amgen, with P&L responsibility for all U.S. and Canadian businesses. Daly also served as vice president and general manager for Amgen’s Oncology Business Unit.
Mr. Daly began his career in the pharmaceutical industry at GlaxoSmithKline where he held positions of increasing responsibility, including senior vice president and general manager of the company’s Respiratory and Anti-infective Business Unit, as well as senior vice president of U.S. Marketing. He earned a Bachelor of Science degree in Pharmacy and Master of Business Administration from the State University of New York at Buffalo.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly for its ENHANZE™ drug delivery platform. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the Company's future expectations and plans for growth in 2016, the development and commercialization of product candidates and the potential benefits and attributes of such product candidates) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected fluctuations or changes in revenues, including revenues from collaborators, unexpected results or delays in development of product candidates and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 29, 2016.
# # #
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Apr 2023 to Apr 2024
